15-Year watch begins for experimental transplant therapy
NCT ID NCT05987527
First seen Jan 05, 2026 · Last updated Jun 19, 2026 · Updated 27 times
Summary
This study follows 11 kidney transplant patients who received an experimental cell therapy called TX200-TR101 in an earlier trial. Researchers will monitor them for up to 15 years to check for long-term side effects and how well their transplanted kidney is doing. The goal is to see if this personalized therapy is safe over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for END STAGE RENAL DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Erasmus MC, University Medical Center
Rotterdam, Netherlands
-
Leiden University Medical Centre
Leiden, Netherlands
-
Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom
-
University Hospitals Leuven
Leuven, Belgium
-
University Medical Center Groningen
Groningen, Netherlands
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TX200-TR101 (a personalized cell therapy using the patient's own modified immune cells)
What this could lead to
If successful, this could show that TX200-TR101 is safe over many years and may help reduce the need for lifelong anti-rejection drugs in kidney transplant patients.
What could go wrong
This is a small, early follow-up study (only 11 people) and does not test whether the therapy works. Long-term risks or side effects may still emerge.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.